Johnson & Johnson logo

Johnson & Johnson (JNJ)

Market Closed
17 Jul, 20:00
NYSE NYSE
$
162. 98
-1.8
-1.09%
$
377.32B Market Cap
29.06 P/E Ratio
4.96% Div Yield
11,013,070 Volume
9.91 Eps
$ 164.78
Previous Close
Day Range
162.3 164.7
Year Range
140.68 169.99
Want to track JNJ and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 88 days
Johnson & Johnson (NYSE: JNJ) Live Earnings Updates: Will The Dividend Champion Deliver?

Johnson & Johnson (NYSE: JNJ) Live Earnings Updates: Will The Dividend Champion Deliver?

Johnson & Johnson reports before the bell today. The stock is popular in part thanks to its 3.3% dividend yield.

247wallst | 1 day ago
Johnson & Johnson's stock rallies after earnings beat and outlook raised, amid strength in heart and cancer treatments

Johnson & Johnson's stock rallies after earnings beat and outlook raised, amid strength in heart and cancer treatments

Shares of Johnson & Johnson JNJ-1.05% climbed 1.6% in premarket trading Wednesday, after the drugmaker beat second-quarter earnings expectations and raised its full-year outlook, amid strength in sales of cancer treatments and heart health monitoring products.

Marketwatch | 1 day ago
Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

Johnson & Johnson beats profit estimates on strong Darzalex, medtech sales

Johnson & Johnson reported second-quarter profit and raised its full-year sales forecast by around $2 billion on Wednesday as strong demand for its cancer drug, Darzalex, and strength in its medical device business helped it beat Wall Street expectations.

Reuters | 1 day ago
Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

Should J&J Stock Be in Your Portfolio Ahead of Q2 Earnings?

JNJ eyes Q2 growth with strong drug sales and new launches, but Stelara biosimilars and MedTech headwinds loom.

Zacks | 3 days ago
Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?

Johnson & Johnson: Buy JNJ Stock Ahead of Its Upcoming Earnings?

Johnson & Johnson (NYSE:JNJ) is set to report its earnings on Wednesday, July 16, 2025. For traders focused on events, analyzing historical stock behavior surrounding earnings reports can be an important strategy, possibly improving the odds in your favor.

Forbes | 3 days ago
Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics

Unveiling Johnson & Johnson (JNJ) Q2 Outlook: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Johnson & Johnson (JNJ), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.

Zacks | 6 days ago
I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream

I Have Invested in Dividends For 15 Years—These Dividend Aristocrats Built My Passive Income Stream

These dividend aristocrats haven't disappointed me in 15 years and won't disappoint you either.

247wallst | 1 week ago
Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Johnson & Johnson (JNJ) Expected to Beat Earnings Estimates: Should You Buy?

Johnson & Johnson (JNJ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 1 week ago
Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Why Johnson & Johnson (JNJ) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 1 week ago
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?

JNJ's growth outlook, rising estimates, and strength in Innovative Medicine give it an edge over Pfizer in 2025.

Zacks | 1 week ago
Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?

Johnson & Johnson: What To Expect From The Upcoming Q2 Earnings?

JNJ which has outperformed the S&P 500 and other large-cap healthcare peers in H1-2025, now faces a crucial test with Q2 results due to be announced on the 16th ofJuly. JNJ has a long history of beating consensus EPS estimates by 5.5% on average. The Q2 sales growth could potentially be the weakest of the 4 quarters of the year.

Seekingalpha | 1 week ago
3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend

3 Must-Buy Dividend Stocks if You Only Have $5,000 to Spend

The vast majority of investors don't have hundreds of thousands to bet on each stock.

247wallst | 1 week ago
Loading...
Load More